Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celldex Therapeutics, Inc. (CLDX : NSDQ)

• Company Description    CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Number of Employees: 186

• Price / Volume Information    Yesterday's Closing Price: $27.16 Daily Weekly Monthly 20 Day Moving Average: 714,288 shares Shares Outstanding: 66.45 (millions) Market Capitalization: $1,804.77 (millions) Beta: 1.19 52 Week High: $30.50 52 Week Low: $14.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.24% -8.09% 12 Week -1.38% -2.97% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 53 FRONTAGE ROAD SUITE 220 - HAMPTON,NJ 08827 USA ph: 908-200-7500 fax: 908-454-1911 ir@celldex.com http://www.celldex.com

• General Corporate Information    Officers Anthony S. Marucci - President; Chief Executive Officer and Director Karen L. Shoos - Chairman and Director Sam Martin - Senior Vice President; Chief Financial Officer and Keith L. Brownlie - Director Cheryl L. Cohen - Director Peer Information Celldex Therapeutics, Inc. (CORR.) Celldex Therapeutics, Inc. (RSPI) Celldex Therapeutics, Inc. (CGXP) Celldex Therapeutics, Inc. (BGEN) Celldex Therapeutics, Inc. (GTBP) Celldex Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117B202 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 66.45 Most Recent Split Date: 2.00 (0.07:1) Beta: 1.19 Market Capitalization: $1,804.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.02 Price/Cash Flow: - Price / Sales: 311.65 EPS Growth vs. Year Ago Period: -57.81% vs. Previous Quarter: -18.82% Sales Growth vs. Year Ago Period: -70.78% vs. Previous Quarter: 5.04% ROE 12/31/25 - - 09/30/25 - -33.22 06/30/25 - -27.61 ROA 12/31/25 - - 09/30/25 - -31.26 06/30/25 - -26.20 Current Ratio 12/31/25 - - 09/30/25 - 13.01 06/30/25 - 19.67 Quick Ratio 12/31/25 - - 09/30/25 - 13.01 06/30/25 - 19.67 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -3,446.88 Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -3,446.88 Pre-Tax Margin 12/31/25 - - 09/30/25 - -8,635.85 06/30/25 - -3,446.88 Book Value 12/31/25 - - 09/30/25 - 9.00 06/30/25 - 9.87 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©